Evidence map›Paper›PMID 42636229›Full record

ArticlePloS one2026

Role of connexin 43 in hyperoxia-induced bronchopulmonary dysplasia and associated pulmonary hypertension.

Claire-Marie Pilard, Laure Gassiat, Guillaume Cardouat, Isabel Gauthereau, Paul Robillard, Eric Dumas-de-la-Roque, Fanny Sauvestre, Fanny Pelluard, Sophie Berenguer, Melie Sarreau and 7 more

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Claire-Marie PilardUniv. Bordeaux, INSERM, CRCTB, U 1045, Pessac, France.ORCID https://orcid.org/0009-0003-6023-0772
Laure GassiatUniv. Bordeaux, INSERM, CRCTB, U 1045, Pessac, France.
Guillaume CardouatUniv. Bordeaux, INSERM, CRCTB, U 1045, Pessac, France.
Isabel GauthereauUniv. Bordeaux, INSERM, CRCTB, U 1045, Pessac, France.
Paul RobillardUniv. Bordeaux, INSERM, CRCTB, U 1045, Pessac, France.
Eric Dumas-de-la-RoqueUniv. Bordeaux, INSERM, CRCTB, U 1045, Pessac, France.
Fanny SauvestreCHU de Bordeaux, Pathology Department, Bordeaux, France.
Fanny PelluardCHU de Bordeaux, Pathology Department, Bordeaux, France.
Sophie BerenguerCHU de Bordeaux, Pathology Department, Bordeaux, France.
Melie SarreauCHU de Bordeaux, Pathology Department, Bordeaux, France.
Loïc SentilhesCHU de Bordeaux, Obstetrics and Gynecology Department, Bordeaux, France.
Fréderic CoatlevenCHU de Bordeaux, Obstetrics and Gynecology Department, Bordeaux, France.
Marie VincienneCHU de Bordeaux, Obstetrics and Gynecology Department, Bordeaux, France.
Roger MarthanUniv. Bordeaux, INSERM, CRCTB, U 1045, Pessac, France.
Patrick BergerUniv. Bordeaux, INSERM, CRCTB, U 1045, Pessac, France.
Véronique Freund-MichelUniv. Bordeaux, INSERM, CRCTB, U 1045, Pessac, France.
Christelle GuibertUniv. Bordeaux, INSERM, CRCTB, U 1045, Pessac, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Premature infants frequently require oxygen supplementation due to lung immaturity, exposing them to the risk of bronchopulmonary dysplasia (BPD), a chronic lung disease characterized by arrested alveolar growth and inflammation. Connexin 43-dependent gap junctions (Cx43-GJ) regulate intercellular communication during lung development and inflammatory responses, but their involvement in BPD remains incompletely defined. This study aimed to assess the contribution of Cx43-GJ in experimental BPD and to evaluate whether selective pharmacological inhibition of Cx43 modulates hyperoxia-induced lung injury and pulmonary hypertension. Newborn rats were exposed to normoxia or hyperoxia (90% O2) for 14 days and treated daily with the Cx43-GJ inhibitor 43Gap26 or vehicle. Human fetal pulmonary artery smooth muscle cells (HfPA-SMC) were exposed to 21% O2 or 60% O2 and treated with or without 43Gap26 for 48 hours. Lung morphology, function, surfactant protein expression, extracellular matrix markers, macrophage phenotype, cytokine secretion, and oxidative stress markers were assessed. In vivo, 43Gap26 reduced hyperoxia-induced Cx43 overexpression and partially improved alveolarization. However, 43Gap26 failed to prevent alterations in lung function, decreased surfactant protein-B expression, extracellular matrix remodeling, macrophage M2 polarization, increased tissue inhibitor of metalloproteinase-1 secretion, pulmonary hypertension, or mortality. Inhibition of Cx43 was also associated with reduced markers of type II alveolar epithelial cell expression. In HfPA-SMC, 43Gap26 did not modify hyperoxia-induced secretion of pro-inflammatory cytokines, despite increased Cx43 expression. Classical markers of oxidative damage were not significantly increased under our experimental conditions, although heme oxygenase-1 expression was elevated. Overall, pharmacological inhibition of Cx43 partially restored alveolar structure but did not prevent major pathological features of experimental BPD or pulmonary hypertension. These findings suggest that Cx43-GJ signaling is involved in the regulation of alveolar structure during hyperoxic lung injury, but its pharmacological inhibition alone is insufficient to prevent the complex structural and vascular alterations characteristic of experimental BPD.

Indexed as

Bronchopulmonary DysplasiaConnexin 43HyperoxiaHypertension, PulmonaryAnimalsAnimals, NewbornGap JunctionsHumansLungMyocytes, Smooth MuscleOxidative StressPeptidesPulmonary ArteryRatsConnexin 43Gap 26 peptidePeptides

Identifiers

PMID42636229
PMCPMC13502688

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.